Saudi Central Bank Increases Holdings in Zoetis Inc. $ZTS

Saudi Central Bank increased its position in Zoetis Inc. (NYSE:ZTS) by 81.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 29,436 shares of the company’s stock after buying an additional 13,170 shares during the quarter. Saudi Central Bank’s holdings in Zoetis were worth $2,115,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Zoetis during the second quarter worth approximately $25,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the last quarter. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis in the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the 1st quarter valued at $28,000. Finally, Root Financial Partners LLC grew its holdings in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.1%

Shares of ZTS opened at $75.70 on Tuesday. The stock has a market capitalization of $31.28 billion, a P/E ratio of 12.47, a PEG ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $155.15. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a fifty day simple moving average of $75.58 and a two-hundred day simple moving average of $93.26.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZTS. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Piper Sandler decreased their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. UBS Group lowered their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Finally, Citigroup reduced their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average price target of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.